- ECONOMIC IMPACT -

Latest update: 21 October 

Many economists have cut their GDP forecasts. The 2020 consensus forecast for GDP growth is currently negative and many predict a recession.

World Trade Organization forecasts the volume of world merchandise trade to shrink by 9.2% in 2020 followed by an estimated rise of 7.2% in 2021.

-4.4%

IMF has revised its 2020 global GDP forecast to -4.4% from an estimate of -4.9% made in June.

88-115 million

Covid-19 to push 88-115 million people into extreme poverty in 2020, according to the World Bank.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 10 November 

Vaccine development

38%

The unproven technology of mRNA vaccines was seen to be the most promising by GlobalData survey respondents, with 38% reporting this may offer the best hope of addressing the outbreak. This is likely due to the rapid nature which saw mRNA vaccines enter the clinic.

$328m

Clover Biopharmaceuticals will receive up to $328m from the Coalition for Epidemic Preparedness Innovation for the late-stage development of its Covid-19 vaccine candidate.

clinical trial results 

Pfizer and BioNTech announced positive results from the interim analysis of their Covid-19 vaccine candidate.


The vaccine showed greater than 90% efficacy in the first 94 confirmed Covid-19 cases that occurred in trial participants without prior SARS-CoV-2 infection, greatly exceeding the efficacy bar of 50% set by the US Food and Drug Administration.


The announcement comes less than one year since SARS-CoV-2 was identified and seven months after the companies started their first Phase I study. More than 43,000 participants from diverse backgrounds were enrolled in the Phase III trial.


However, the 90% efficacy reported in the interim analysis can still decrease in the final analysis, which will include 164 cases of confirmed Covid-19.

Key pharma market developments

Share this article

Go to article: Home | The logistics of delivering a global vaccineGo to article: In this issueGo to article: ContentsGo to article: MimotopesGo to article: SHL MedicalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: SwiftpakGo to article: CommentGo to article: Long HCC pipeline marks change for a previously stagnant marketGo to article: Pfizer and BioNTech’s Covid-19 vaccine candidate shows 90% efficacyGo to article: Blockchain-enabled hospital can provide real-world dataGo to article: The increasing influence of industry sponsors along the pandemic timelineGo to article: Digitalisation in pharmaceutical manufacturingGo to article: VEGA AustraliaGo to article: KugelmeiersGo to article: Unither PharmaceuticalsGo to article: In DepthGo to article: Special delivery: the logistics of curing Covid-19 Go to article: Will there ever be an HIV vaccine?Go to article: Predicting Covid-19 vaccine approvals with OpylGo to article: Unequal access: understanding cancer treatment disparity in EuropeGo to article: ‘Trustpilot’ for medicines: can DrugsDiscovered help pharma be patient centric?Go to article: Q&A: investing in innovative biotechs with Novo VenturesGo to article: Gold standard: why are Phase III trials so critical?Go to article: Brewprint: using yeast to make plant-based drugsGo to article: Air FranceGo to article: Zenatek Company Insight Go to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue